Wegovy, Zepbound and Saxenda are three injection brands with U.S. weight-management indications. They contain semaglutide, tirzepatide and liraglutide, respectively. The diabetes brands Ozempic and Mounjaro contain two of those ingredients but have different approvals.
Start with the exact product and formulation, not a list of ingredient names. The comparison below focuses on these commonly discussed incretin medicines; it is not an exhaustive list of every injectable treatment or a REMEVi product catalog.
| Injection | Ingredient and receptor action | Schedule | U.S. approved-use summary |
|---|---|---|---|
| Wegovy | Semaglutide; GLP-1 | Weekly | Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular-risk reduction in eligible adults; adult noncirrhotic MASH with F2–F3 fibrosis |
| Zepbound | Tirzepatide; GIP and GLP-1 | Weekly | Adult weight management; moderate-to-severe obstructive sleep apnea in adults with obesity |
| Saxenda | Liraglutide; GLP-1 | Daily | Weight management, including eligible adolescents 12+ with obesity and body weight over 60 kg |
| Ozempic | Semaglutide; GLP-1 | Weekly | Adult type 2 diabetes; specified cardiovascular and kidney-risk indications in adults with type 2 diabetes |
| Mounjaro | Tirzepatide; GIP and GLP-1 | Weekly | Type 2 diabetes in adults and children 10+; major cardiovascular-risk reduction in adults with type 2 diabetes at high risk |
Sources: Wegovy, Zepbound, Saxenda, Ozempic injection, Mounjaro, section 1 of each label.
For adult weight management, the weight-management brands cover obesity or overweight with a weight-related condition, together with nutrition and physical activity changes. Wegovy’s cardiovascular indication requires established cardiovascular disease and obesity or overweight. Its MASH indication is an accelerated approval for a specific liver condition; it is not a general liver-health claim.
Pediatric approvals are product-specific and do not establish availability through REMEVi. See the eligibility guide for the difference between weight-management and diabetes criteria.
GLP-1 receptor agonists affect appetite, slow stomach emptying and help regulate blood glucose. Their glucose-dependent action does not eliminate hypoglycemia risk, particularly when used with insulin or a sulfonylurea. Tirzepatide also activates GIP receptors.
Semaglutide is a GLP-1 receptor agonist. A molecule illustration does not show a specific finished medication.
Two receptors do not establish that a treatment is best for everyone. The tirzepatide mechanism guide separates what the molecule does from what trials of specific products measured.
All three weight-management injections begin with lower doses and increase according to their own labels. They do not share one escalation schedule or one missed-dose rule. A prescriber may need to reassess the dose after an interruption or significant side effects.
A pen, prefilled syringe and vial can require different handling even within a brand. Get training for the actual presentation you receive. For a compounded vial, confirm the dose in mg, its concentration and the syringe marking with the pharmacy; “units” alone are not a medication dose. Read semaglutide dosing and measurement, missed doses and travel/storage.
Yes. Wegovy has daily tablets for adult weight management and cardiovascular-risk reduction in eligible adults. Its injection-only MASH and adolescent indications do not apply to the tablets. Ozempic also has tablets with diabetes-related indications. These oral products have different doses and cannot be substituted milligram for milligram. Wegovy label, Ozempic tablet label
Oral delivery does not by itself imply weak treatment, and injection does not guarantee a better result. Compare the actual medicine, administration requirements and evidence in pills versus injections and Foundayo versus Wegovy pills.
A compounded semaglutide or tirzepatide preparation is not FDA-approved or a generic version of these brands. It cannot inherit their approved indications, dosing instructions or trial outcomes. Ask why the preparation meets a medical need that an available approved medicine cannot meet, and ask the pharmacy for product-specific instructions. FDA: risks of compounded drugs
The evaluation considers your diagnosis, medicines, past treatment, pregnancy plans, gastrointestinal symptoms and relevant risks. Personal or family medullary thyroid carcinoma, MEN2 and serious allergy to a product are among the contraindications listed for these medicines. Significant symptoms may require evaluation before treatment.
REMEVi includes clinician-required GLP-1 labs; the clinician sets the tests and timing. Care is available in English and Spanish in 49 states and Washington, DC, excluding Louisiana. Review lab testing and current pricing before your consultation. See if you qualify.
Educational information, not medical advice. Product choice and eligibility require a licensed clinician; individual results vary.
Wegovy contains semaglutide, Zepbound contains tirzepatide and Saxenda contains liraglutide. These brands have weight-management indications for specific populations. Ozempic and Mounjaro are different products with diabetes indications.
Wegovy and Zepbound injections are weekly; Saxenda is daily. Each has its own dose-escalation instructions. A daily tablet or compounded preparation cannot use an injection's instructions by default.
Yes. Wegovy has an approved daily tablet for eligible adults, and other prescription oral options exist. Tablets have product-specific administration and eligibility rules; the route alone does not establish which treatment is more effective or appropriate.
The clinician weighs the treatment indication, medical history, other medicines, tolerability and access. Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1. Receptor count does not decide which is right for a person.
Free 1-minute quiz, then a 2-minute intake if you qualify. A licensed clinician reviews your information. If prescribed, medication is delivered to your door.
See if you qualifyFree · about 1 minute · no card required
